吕万良团队在靶向性基因编辑系统抗转移性乳腺癌研究方面取得进展

中国药学(英文版) ›› 2021, Vol. 30 ›› Issue (10): 851-852.

吕万良团队在靶向性基因编辑系统抗转移性乳腺癌研究方面取得进展

北京大学药学院天然药物及仿生药物国家重点实验室

北京大学药学院天然药物及仿生药物国家重点实验室

收稿日期:2021-10-10 修回日期:2021-10-10 接受日期:2021-10-10 出版日期:2021-10-24 发布日期:2021-10-30

The group of Professor Wanliang Lu has made progress in targeted gene editing systems against metastatic breast cancer

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

Received:2021-10-10 Revised:2021-10-10 Accepted:2021-10-10 Online:2021-10-24 Published:2021-10-30

摘要/Abstract

摘要：

10月7日, 北京大学药学院天然药物及仿生药物国家重点实验室吕万良课题组在国际著名学术期刊《Bioactive Materials》在线发表了题为“Targeted core-shell nanoparticles for precise CTCF gene insert in treatment of metastatic breast cancer”的研究工作。

Supporting:

北京大学药学院天然药物及仿生药物国家重点实验室. 吕万良团队在靶向性基因编辑系统抗转移性乳腺癌研究方面取得进展[J]. 中国药学(英文版), 2021, 30(10): 851-852.

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The group of Professor Wanliang Lu has made progress in targeted gene editing systems against metastatic breast cancer[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(10): 851-852.